دورية أكاديمية
Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis.
| العنوان: | Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. |
|---|---|
| المؤلفون: | Parry H; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Bruton R; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Tut G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Ali M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Stephens C; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Greenwood D; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Faustini S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Hughes S; Department of Immunology, Birmingham Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK., Huissoon A; Department of Immunology, Birmingham Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK., Meade R; Harborne Medical Practice, Harborne, Birmingham, UK., Brown K; National Infection Service, Public Health England, Colindale, London, UK., Amirthalingam G; National Infection Service, Public Health England, Colindale, London, UK., Otter A; National Infection Service, Public Health England, Porton Down, Salisbury, UK., Hallis B; National Infection Service, Public Health England, Porton Down, Salisbury, UK., Richter A; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Zuo J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Moss P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. |
| المصدر: | The lancet. Healthy longevity [Lancet Healthy Longev] 2021 Sep; Vol. 2 (9), pp. e554-e560. Date of Electronic Publication: 2021 Aug 12. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101773309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-7568 (Electronic) Linking ISSN: 26667568 NLM ISO Abbreviation: Lancet Healthy Longev |
| أسماء مطبوعة: | Original Publication: [Oxford] : Elsevier Ltd., [2020]- |
| مواضيع طبية MeSH: | COVID-19* , COVID-19 Vaccines*, Aged, 80 and over ; Antibodies, Viral ; BNT162 Vaccine ; ChAdOx1 nCoV-19 ; Humans ; Leukocytes, Mononuclear ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus ; Vaccination |
| مستخلص: | Background: In several countries, extended interval COVID-19 vaccination regimens are now used to accelerate population coverage, but the relative immunogenicity of different vaccines in older people remains uncertain. In this study we aimed to assess the antibody and cellular responses of older people after a single dose of either the BNT162b2 vaccine (tozinameran; Pfizer-BioNTech) or ChAdOx1 nCoV-19 vaccine (Oxford University-AstraZeneca). Methods: Participants aged 80 years or older, who did not live in a residential or care home or require assisted living, and had received a single dose of either the BNT162b2 vaccine or ChAdOx1 nCoV-19 vaccine were eligible to participate. Participants were recruited through local primary care networks in the West Midlands, UK. Blood samples and dried blood spots were taken 5-6 weeks after vaccination to assess adaptive immune responses using Elecsys electrochemiluminescence immunoassay and cellular responses by ELISpot. Primary endpoints were percentage response and quantification of adaptive immunity. Findings: Between Dec 29, 2020, and Feb 28, 2021, 165 participants were recruited and included in the analysis. 76 participants had received BNT162b2 (median age 84 years, IQR 82-89; range 80-98) and 89 had received ChAdOx1 nCoV-19 (median age 84 years, 81-87; 80-99). Antibody responses against the spike protein were detectable in 69 (93%) of 74 BNT162b2 vaccine recipients and 77 (87%) of 89 ChAdOx1 nCoV-19 vaccine recipients. Median antibody titres were of 19·3 U/mL (7·4-79·4) in the BNT162b2 vaccine recipients and 19·6 U/mL (6·1-60·0) in the ChAdOx1 nCoV-19 vaccine recipients (p=0·41). Spike protein-specific T-cell responses were observed in nine (12%) of 73 BNT162b2 vaccine recipients and 27 (31%) of 88 ChAdOx1 nCoV-19 vaccine recipients, and median responses were three-times higher in ChAdOx1 nCoV-19 vaccine recipients (24 spots per 1 × 10 6 peripheral blood mononuclear cells) than BNT162b2 vaccine recipients (eight spots per 1 × 10 6 peripheral blood mononuclear cells; p<0·0001). Humoral and cellular immune responses against spike protein were correlated in both cohorts. Evidence of previous SARS-CoV-2 infection was seen in eight participants (n=5 BNT162b2 recipients and n=3 ChAdOx1 nCoV-19 recipients), and was associated with 691-times and four-times increase in humoral and cellular immune responses across the whole cohort. Interpretation: Single doses of either BNT162b2 or ChAdOx1 nCoV-19 in older people induces humoral immunity in most participants, and is markedly enhanced by previous infection. Cellular responses were weaker, but showed enhancement after the ChAdOx1 nCoV-19 vaccine at the 5-6 week timepoint. Funding: Medical Research Council, National Institute for Health Research, and National Core Studies. Competing Interests: We declare no competing interests. (© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.) |
| التعليقات: | Comment in: Lancet Healthy Longev. 2021 Sep;2(9):e529-e530. doi: 10.1016/S2666-7568(21)00205-1. (PMID: 34430953) |
| References: | Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989) Sci Adv. 2021 Mar 19;7(12):. (PMID: 33608249) J Infect Dis. 2020 Aug 17;222(6):979-988. (PMID: 32320465) Lancet. 2021 Mar 20;397(10279):1057-1058. (PMID: 33640038) N Engl J Med. 2021 Apr 15;384(15):1412-1423. (PMID: 33626250) J Infect Dis. 2019 Jun 5;220(1):46-56. (PMID: 30796818) Semin Immunol. 2018 Dec;40:83-94. (PMID: 30501873) N Engl J Med. 2021 Apr 8;384(14):1372-1374. (PMID: 33691060) Nat Rev Immunol. 2009 Mar;9(3):185-94. (PMID: 19240757) BMJ. 2021 May 13;373:n1088. (PMID: 33985964) Lancet Microbe. 2022 Jan;3(1):e21-e31. (PMID: 34778853) Immunol Rev. 2018 Jul;284(1):91-105. (PMID: 29944766) Elife. 2021 Sep 29;10:. (PMID: 34586068) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) N Engl J Med. 2021 May 13;384(19):1824-1835. (PMID: 33440088) |
| معلومات مُعتمدة: | MC_PC_20031 United Kingdom MRC_ Medical Research Council; MC_PC_20060 United Kingdom MRC_ Medical Research Council; MR/V028448/1 United Kingdom MRC_ Medical Research Council |
| المشرفين على المادة: | 0 (Antibodies, Viral) 0 (COVID-19 Vaccines) 0 (Spike Glycoprotein, Coronavirus) 0 (spike protein, SARS-CoV-2) B5S3K2V0G8 (ChAdOx1 nCoV-19) N38TVC63NU (BNT162 Vaccine) |
| تواريخ الأحداث: | Date Created: 20210817 Date Completed: 20220830 Latest Revision: 20240815 |
| رمز التحديث: | 20240815 |
| مُعرف محوري في PubMed: | PMC8357462 |
| DOI: | 10.1016/S2666-7568(21)00169-0 |
| PMID: | 34401865 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2666-7568 |
|---|---|
| DOI: | 10.1016/S2666-7568(21)00169-0 |